L & S Advisors Inc Has $6.70 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

L & S Advisors Inc reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.3% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 15,065 shares of the medical equipment provider’s stock after selling 1,734 shares during the quarter. L & S Advisors Inc’s holdings in Intuitive Surgical were worth $6,702,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Gilbert & Cook Inc. grew its stake in Intuitive Surgical by 6.5% in the fourth quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after acquiring an additional 211 shares during the period. Financial Advocates Investment Management raised its holdings in shares of Intuitive Surgical by 6.9% during the fourth quarter. Financial Advocates Investment Management now owns 1,635 shares of the medical equipment provider’s stock valued at $552,000 after acquiring an additional 106 shares in the last quarter. AMG National Trust Bank raised its position in shares of Intuitive Surgical by 8.0% in the 4th quarter. AMG National Trust Bank now owns 1,834 shares of the medical equipment provider’s stock worth $619,000 after acquiring an additional 136 shares in the last quarter. TrinityPoint Wealth LLC increased its stake in shares of Intuitive Surgical by 21.5% in the 4th quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock worth $365,000 after acquiring an additional 191 shares in the last quarter. Finally, Hillsdale Investment Management Inc. grew its holdings in Intuitive Surgical by 80.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 280 shares of the medical equipment provider’s stock worth $94,000 after purchasing an additional 125 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Amy L. Ladd sold 450 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares in the company, valued at $402,519.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock worth $25,528,753 in the last quarter. 0.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have commented on ISRG. Robert W. Baird increased their target price on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Citigroup upped their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. BTIG Research boosted their price target on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Evercore ISI dropped their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, Morgan Stanley increased their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Stock Up 0.3 %

Shares of Intuitive Surgical stock opened at $491.39 on Tuesday. The business’s fifty day moving average is $464.67 and its two-hundred day moving average is $422.79. The firm has a market cap of $174.30 billion, a PE ratio of 88.70, a P/E/G ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the company earned $1.18 earnings per share. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.